PS-C19-6: STUDY ON THE EFFICACY AND SAFETY OF TENG FU JIANGYA TABLET IN THE TREATMENT OF HYPERTENSION

Abstract

Background: At present, the most important task of cardiovascular disease health management that is to improving the blood pressure compliance rate of Hypertensive Patients. Traditional Chinese medicine (TCM) is an important part of complementary and alternative medicine. Research shows that traditional Chinese medicine has antihypertensive effect from multiple pathways and multiple targets. However, lack of clinical evidence-based medical evidence of TCM in the treatment of hypertension. The purpose of this study was to investigate the efficacy and safety of Teng Fu Jiangya tablet (TJT) in the treatment of hypertension. Methods: A prospective, randomized, single-blind, placebo-controlled clinical trial was conducted in order to evaluating the effectiveness and safety of TJT in the treatment of grade 1 hypertension (N = 130). On this basis, a multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted on the treatment of grade 2 hypertension with TJT combined with valsartan / amlodipine (N = 288). During the experiment, the efficacy index of the subjects were recorded for effectiveness evaluation, and the safety index and adverse reaction events of the subjects were recorded for safety evaluation. Results: 1. After 4 weeks of intervention in patients with grade 1 hypertension, there were significantly difference in the SBP and DBP compared with placebo group. The compliance rate of blood pressure of TJT group is 67.19% and in placebo group is 43.08%. TJT can improve the standard rate of blood pressure. There were also significantly difference in the level of Arachidonic acid, the thromboxaneB2 and the Prostaglandin E2 between the two groups. And there was no serious adverse event reported. 2. After 4 weeks of intervention in patients with grade 2 hypertension, in accordance blood pressure compliance rate, the systolic blood pressure compliance rate of the treatment group was 61.65%, and the placebo group was 37.68%. The treatment group could more effectively reduce the levels of arachidonic acid and thromboxane B2 and increase the level of prostaglandin E2, reduce inflammatory factors, so as to reduce the inflammatory. Conclusion: TJT tablet has good effectiveness and safety in the clinical treatment of hypertension. TJT also can effectively reduce the damage of vascular endothelium in the treatment of hypertension. Therefore, TJT play a key role in reducing blood pressure and protecting target organ damage. This is an innovative method for the treatment of hypertension.